Paying users zone. Data is hidden behind: .
Get 1-month access to Stryker Corp. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Stryker Corp. pages available today for free:
Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Stryker Corp., solvency ratios (quarterly data)
Based on: 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp.’s debt to equity ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp.’s debt to capital ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp.’s debt to assets ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp.’s financial leverage ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Debt to Equity
Stryker Corp., debt to equity calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Current maturities of debt | ||||||||||||||||||||||||||
| Long-term debt, excluding current maturities | ||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||
| Total Stryker shareholders’ equity | ||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
| Becton, Dickinson & Co. | ||||||||||||||||||||||||||
| Boston Scientific Corp. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).
1 Q4 2020 Calculation
Debt to equity = Total debt ÷ Total Stryker shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp.’s debt to equity ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to Capital
Stryker Corp., debt to capital calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Current maturities of debt | ||||||||||||||||||||||||||
| Long-term debt, excluding current maturities | ||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||
| Total Stryker shareholders’ equity | ||||||||||||||||||||||||||
| Total capital | ||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
| Becton, Dickinson & Co. | ||||||||||||||||||||||||||
| Boston Scientific Corp. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).
1 Q4 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp.’s debt to capital ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to Assets
Stryker Corp., debt to assets calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Current maturities of debt | ||||||||||||||||||||||||||
| Long-term debt, excluding current maturities | ||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
| Becton, Dickinson & Co. | ||||||||||||||||||||||||||
| Boston Scientific Corp. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).
1 Q4 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp.’s debt to assets ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
Financial Leverage
Stryker Corp., financial leverage calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Total Stryker shareholders’ equity | ||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Financial leverage1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
| Becton, Dickinson & Co. | ||||||||||||||||||||||||||
| Boston Scientific Corp. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22).
1 Q4 2020 Calculation
Financial leverage = Total assets ÷ Total Stryker shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp.’s financial leverage ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |